| Literature DB >> 26999172 |
Maricica Pacurari1,2, Kristine Lowe3, Paul B Tchounwou4,5, Ramzi Kafoury6,7.
Abstract
The respiratory system represents the main gateway for nanoparticles' entry into the human body. Although there is a myriad of engineered nanoparticles, carbon nanoparticles/nanotubes (CNPs/CNTs) have received much attention mainly due to their light weight, very high surface area, durability, and their diverse applications. Since their discovery and manufacture over two decades ago, much has been learned about nanoparticles' interactions with diverse biological system models. In particular, the respiratory system has been of great interest because various natural and man-made fibrous particles are known to be responsible for chronic and debilitating lung diseases. In this review, we present up-to-date the literature regarding the effects of CNTs or carbon nanofibers (CNFs) on the human respiratory system with respect to respiratory toxicity pathways and associated pathologies. This article is intended to emphasize the potentially dangerous effects to the human respiratory system if inadequate measures are used in the manufacture, handling, and preparation and applications of CNP or CNP-based products.Entities:
Keywords: CNF; CNT; exposure levels; respiratory pathology; toxicological pathways
Mesh:
Substances:
Year: 2016 PMID: 26999172 PMCID: PMC4808988 DOI: 10.3390/ijerph13030325
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1CNT-induced toxicological pathways and the associated respiratory pathologies. CNT induce upper and lower respiratory system pathologies in diverse experimental models. The upper part of the figure indicates the toxicological pathways induced by CNT either in vitro or in vivo studies. The shown respiratory pathologies and associated physiological changes in the tissues or biological fluid are those observed in numerous animal studies. ↑, increased expression or increased number; ↓, decreased expression; the long arrow indicated the induction of respective toxicological pathways, pathologies, and associated markers. This figure was prepared from the extensive review of the studies cited in this manuscript and presented in the Reference section.
List of some of the in vivo studies which show CNTs/CNFs toxicity on the respiratory system.
| Year | Types of CNTs/Sources | CNTs Length | Assay Type | Mode of Administration | Dose | Exposure Time | Outcome | Reference |
|---|---|---|---|---|---|---|---|---|
| 2009 | MWCNT +/− defects | <1 μm | Wistar rats | I.P. | 2, 20 mg/animal | 24 months | No mesothelioma | [ |
| 2010 | MWCNT (MWNT-7, Lot # T050831-01, Mitsui & Co. Ltd. 9, Tokyo, Japan) | 1.5 μm | SD rats | I.T. | 0.04, 0.2, 1 mg/kg | 3, 7 days; 1, 3, 6 months | Negative interstitial tissue, absence of fibrosis, MWCNT + Macrophages in alveoli. Lower case for macrophages. | [ |
| 2004 | CNT (Raw and Purified HiPco NTs, Rice University, Huston, TX, USA); CNT (CaboLex Inc., Lexington, KY, USA) | <1 μm | mice | I.T. | 0.1, 0.5 mg/animal | 7, 90 days | Epitheloid granulomas, interstitial inflammation, lung necrosis; high dose induced 60% death | [ |
| 2009 | MWCNT (Bussan Nanotech Research, Ibaraki, Japan); SES Research (TX, USA) | 3–30 μm, several μm | ICR mice | I.T. | 25, 50 μg | 6 weeks | Exacerbation of allergic murine airway inflammation | [ |
| 2012 | MWCNT (Mitsui MWCNT-7, No. 060125-01k, Tokyo, Japan) | <5 μm | p53 +/− mice | I.P. | 0.3 mg/animal | 1 year | Mesothelioma | [ |
| 2013 | MWCNT (MWCNT-7, lot # 06122031, Hodogaya, Japan) | C57BL6J | Inhal. | 5 mg/m3, 5 h/d, 4 d/wk, 12 d | 1, 14, 84, 168, 336 days | Pulmonary inflammation, progressive collagen in alveolar regions after 336 days | [ | |
| 2013 | CNF (Statoil and Elkem Carbon AS, Kristiansand, Norway) | 5–10 | BALB/cAnNCrl Mice | Intra-nasal | 400 μg/mouse | 26 days | Modulation of airway responses to allergens; CNT more potent than CNF | [ |
| 2014 | MWCNT (Mitsui-7, MWNT-7, lot #061220-31, Hodogaya, Japan) MCA, MWCNT, MCA + MWCNT | 0.5–5 μm | B6C3F1 | Inhal. | 5 mg/m3, 5 h/d, 5 d/wk, 15 d | 17 months | MCA potentiated MWCNT adenocarcinoma MWCNT alone did not induce adenocarcinoma | [ |
| 2015 | MWCNT | 5.53–6.19 μm | F344 rats | Inhal. | 0.2, 1, 5 mg/m3 | 13 weeks | granulomatousa in females at 1 and 5 mg/m3; in males at 0.2 mg/m3 fibrosis | [ |
| 2015 | MWCNT CNTsmall (NC700, Nanocyl, Sambreville, Belgium; 13% impurities); CNTlarge (NM-401, European Joint Research Centre, Ispra, Italy; 3% impurities) | 0.85, 4.05 μm | C57BL/6 mice, female | I.T. | 18, 54, 162 μg/animal | 1, 3, 28 days | Similar inflammatory and acute responses to both types; stronger fibrotic response to CNTlarge than CNTsmall | [ |
| 2010 | SWCNT: CNI, (USA); SES Res. (USA) | 1–15 μm | ICR mice | T. | 50 μg | 6 weeks | Exacerbation of allergic murine airway inflammation | [ |
| 2014 | SWCNT (HiPco, Unidym, Sunnyvale, CA, USA); | 1–3 μm, | C57BL/6 mice | Pharyngeal aspiration, inhalation | 40 μg/animal | 1 year | All particles induced chronic bronchopneumonia, pulmonary fibrosis. CNF > asbestos > SWCNT inflammation, SWCNT were the most fibrogenic, CNF, SWCNT induced K-ras mutations, No tumors | [ |
| 2015 | SWCNTs (Tech. Res. Assoc. for SWCNT, Japan) | CNT-1 (0.51 μm, short); | Wistar rats | I.T. | 0.18, 1.8 mg/kg | 1, 3, 7, 30, 90 days | Lung focal inflammation, neutrophil in alveoli, lung macrophages and cell derby in alveoli, higher CNT burden in CNT-1 than CNT-2 at 90 days | [ |
CNTs, carbon nanotubes; CNFs, carbon nanofiber; IT, intratracheal instillation; Inhal, inhalation; IP, intraperitoneal; MCA, methylcholanthrene.